OR WAIT null SECS
ATMPS Ltd has been granted a patent from the United States Patent and Trademark Office for the use of its Hataali blockchain technology used in personalized medicines.
ATMPS Ltd announced it has been granted a patent from the United States Patent and Trademark Office (USPTO) for Hataali, a blockchain-based data sharing platform used in advanced medicinal therapy products. The company is looking to solidify its technological advantage in the global advanced therapy space and has applications bending in both Europe and Asia.
Hataali possesses an incorruptible data solution that tracks therapies through a complex supply chain and ensures patient safety as well as employs efficient regulatory compliance. This has the potential to create a fully digital solution to the challenges of effectively and safely scaling up production. Without a blockchain-based solution, companies do not have a suitable platform to communicate and coordinate their activities to ensure effective commercialism, according to the company.
The company expects the patent to accelerate the adoption of blockchain technologies. This has the potential to transform the pharma industry by providing a new approach to cell and gene therapy tracking, as well as potentially allowing for more streamlined applications and payment options.
“It’s a big moment for Hataali as it means we have the exclusive use of blockchain—the only technology so far proven to overcome the challenges of effective scale-up—in advanced therapy medicinal products in the United States,” commented Raja Sharif, CEO at Hataali. “Up until now, you have several companies trying to shoehorn in unsuitable old ‘point to point’ technologies as a solution for cell and gene therapy tracking. They have simply not worked, and we expect to take a dominant position over the next few years as it becomes apparent we have the only solution for a cost effective mass roll out of these therapies.”